MedPath

Talarozole

Generic Name
Talarozole
Drug Type
Small Molecule
Chemical Formula
C21H23N5S
CAS Number
201410-53-9
Unique Ingredient Identifier
XKD9N5CJ6W

Overview

Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.

Background

Talarozole has been investigated for the treatment of Psoriasis and Cutaneous Inflammation.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

An Open-Label, Multi-Center Trial in the Treatment of Subjects With Moderate to Severe Plaque Type Psoriasis
Phase 2
Completed
Posted: 2008/07/30
Sponsor:
Stiefel, a GSK Compa...
ID:NCT00725348
An Open Label Trial to Assess the Safety and Efficacy of Oral R115866 in the Treatment Facial Acne
Phase 2
Completed
Posted: 2008/07/30
Sponsor:
Stiefel, a GSK Compa...
ID:NCT00725439
Study on Anti-inflammatory Effects of Topical R115866 Gel
Phase 1
Completed
Posted: 2008/07/21
Sponsor:
Stiefel, a GSK Compa...
ID:NCT00719121
Dose Ranging Study of the Safety and Efficacy of R115966 in Plaque Psoriasis
Phase 2
Completed
Posted: 2008/07/16
Sponsor:
Stiefel, a GSK Compa...
ID:NCT00716144

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy